The Battle for Preferred Status: Winners, Losers, and the Patient Dilemma
Just weeks ago, Eli Lilly’s Zepbound stood at the forefront of the booming weight-loss drug market. That changed overnight when CVS Health’s pharmacy benefit arm, Caremark, removed Zepbound from its standard list of preferred medicines, handing the advantage to its primary rival, Novo Nordisk’s Wegovy. This formulary shake-up will ripple across the insurance landscape, directly affecting millions of Americans seeking newer, more effective weight control options.
What explains this sudden repositioning? CVS, one of the nation’s largest pharmacy benefit managers (PBMs), has capitalized on newly eased drug shortages to pit major pharmaceutical players against one another. The company secured greater access and likely steeper discounts from Novo Nordisk, choosing to promote Wegovy to the top spot on its insurance formularies starting July 1. For Zepbound—hailed only recently as a game-changer in obesity management—this represents a major setback.
Stock market reactions were immediate. CVS shares leapt 10% on the news, Novo Nordisk surged up to 6.5%, while Eli Lilly saw its stock slide nearly 7% in early trading. Beneath these numbers lies a more personal impact: patients currently prescribed Zepbound through CVS-managed plans may now be forced to jump through bureaucratic hoops to stay on their medication or switch therapies altogether. CVS spokesperson David Whitrap confirmed that waivers for medical necessity would exist, but the burden will fall to individuals and doctors to make their case. Is this how we want a healthcare system to operate—where treatment decisions are dictated not by patient welfare, but by corporate wrangling?
Behind the Big Business: Why Pharmacy Benefit Managers Hold So Much Power
A closer look reveals a core problem: pharmacy benefit managers have quietly become some of the most influential gatekeepers in American healthcare. By negotiating with drug manufacturers and determining which drugs are included—or excluded—on insurance coverage lists, PBMs like CVS Caremark control access and shape prices for life-altering medications.
According to a 2023 Kaiser Family Foundation analysis, consolidation among just three PBMs now enables them to oversee prescription coverage for nearly 80% of Americans. This enormous leverage lets PBMs extract substantial discounts. The result? Drug prices can fluctuate not based on cost of production or medical value, but on deals orchestrated behind closed doors. Industry analysts anticipate that PBMs will increasingly use this newfound leverage as GLP-1 drugs—like Wegovy and Zepbound—shift from rare, difficult-to-find therapies to mass-market commodities.
“This is a classic case of what happens when market power goes unchecked,” observes Dr. Arthur Caplan, Professor of Medical Ethics at NYU. “Patients become pawns in a chess game between billion-dollar companies.” PBMs argue that they help employers and insurers secure lower drug prices for members. But transparency is lacking and, as this week’s news demonstrates, patient experience is often collateral damage.
Obesity, Stigma, and the High Cost of Barriers to Care
Obesity is not simply a matter of willpower, as American culture stubbornly tries to suggest. It’s a complex, multifactorial chronic illness that costs the U.S. economy more than $170 billion annually, as estimated by the CDC. The emergence of highly effective GLP-1 agonists like Wegovy and Zepbound brings legitimate hope to people whose lives are limited by this disease—yet access hurdles remain steep.
When PBM-driven exclusions force drug switches or add paperwork, real people suffer. Stories abound: a woman who finally lost weight with Zepbound, only to be told her coverage now favors a different medication. A worker denied the next refill because her insurer, echoing CVS’s policy, abruptly stopped coverage, citing new preferred drug deals. Layered atop these disruptions is the reality of out-of-pocket costs. CVS did announce it will lower the retail price of Wegovy to $499/month for uninsured customers, yet for many, this remains unattainable.
“No one benefits from a system where clinical decisions are made in boardrooms, not exam rooms.”
What’s especially chilling is the way formulary changes deepen structural inequalities. As Harvard’s Dr. Fatima Cody Stanford, a leading obesity medicine specialist, underscores: “Barriers to these medications disproportionately hurt people in lower income brackets, people of color, and those living with multiple chronic conditions.” The U.S. continues to lag behind peer nations in public health benchmarks precisely because life-changing therapies are treated as bargaining chips in opaque negotiations.
The Path Forward: Policy, Transparency, and the Progressive Imperative
Is there a route out of this bind? While companies like Eli Lilly may downplay these PBM maneuvers—pointing to future pipeline drugs and plans to lower prices—policy changes remain essential. Several members of Congress are already calling for reforms to require PBMs to disclose rebate practices and consider patients’ clinical needs, not just financial ones, in coverage decisions. The Federal Trade Commission’s ongoing probe into PBM conduct could help shed light on whether these dominant middlemen wield their market power to the public’s benefit—or detriment.
Transparency and patient advocacy must be the watchwords for lawmakers and regulators as the era of obesity pharmacotherapy advances. Weight-loss medications should not be rationed based on corporate negotiations. Instead, insurance design must reflect the lived experiences of patients who struggle daily against both chronic disease and systemic barriers.
Anyone watching last week’s news understands a basic truth: Healthcare markets, left unregulated, will always prioritize profit over people. A more equitable, just, and responsive healthcare system is possible—if policymakers act to close the gaps that PBMs and pharmaceutical giants exploit. It’s time not just to demand answers, but insist on reforms that put care and dignity above dealmaking.
